PubMed

Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases.

Saini J, Rich MW, Lyss AP.

Ann Intern Med. 1987 Jun;106(6):814-6.PMID: 3579067 [PubMed - indexed for MEDLINE]Related articles

Reversible doxorubicin-induced congestive heart failure.

Cohen M, Kronzon I, Lebowitz A.

Arch Intern Med. 1982 Aug;142(8):1570-1.PMID: 7103641 [PubMed - indexed for MEDLINE]Related articles

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

Schwartz RG, McKenzie WB, Alexander J, Sager P, D'Souza A, Manatunga A, Schwartz PE, Berger HJ, Setaro J, Surkin L, et al.

Am J Med. 1987 Jun;82(6):1109-18.PMID: 3605130 [PubMed - indexed for MEDLINE]Related articles

Selective right ventricular dysfunction following doxorubicin therapy.

Sperber AD, Cantor AA, Biran H, Keynan A.

Isr J Med Sci. 1987 Aug;23(8):896-9.PMID: 3679793 [PubMed - indexed for MEDLINE]Related articles

Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children.

Goorin AM, Borow KM, Goldman A, Williams RG, Henderson IC, Sallan SE, Cohen H, Jaffe N.

Cancer. 1981 Jun 15;47(12):2810-6.PMID: 6942908 [PubMed - indexed for MEDLINE]Related articles

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Swain SM, Whaley FS, Ewer MS.

Cancer. 2003 Jun 1;97(11):2869-79.PMID: 12767102 [PubMed - indexed for MEDLINE]Related articlesFree article

Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.

Palmeri ST, Bonow RO, Myers CE, Seipp C, Jenkins J, Green MV, Bacharach SL, Rosenberg SA.

Am J Cardiol. 1986 Sep 15;58(7):607-13.PMID: 3751931 [PubMed - indexed for MEDLINE]Related articles

Late doxorubicin cardiotoxicity.

Lishner M, Elis A, Ravid M.

Anticancer Drugs. 1992 Aug;3(4):367-9.PMID: 1421431 [PubMed - indexed for MEDLINE]Related articles

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ.

J Clin Oncol. 2005 Nov 1;23(31):7820-6.PMID: 16258084 [PubMed - indexed for MEDLINE]Related articles

Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin.

de Bree E, van Ruth S, Schotborgh CE, Baas P, Zoetmulder FA.

Ann Surg Oncol. 2007 Oct;14(10):3019-26. Epub 2007 Jul 20.PMID: 17638057 [PubMed - indexed for MEDLINE]Related articles

Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.

Batist G, Harris L, Azarnia N, Lee LW, Daza-Ramirez P.

Anticancer Drugs. 2006 Jun;17(5):587-95.PMID: 16702817 [PubMed - indexed for MEDLINE]Related articles

Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.

Mitani I, Jain D, Joska TM, Burtness B, Zaret BL.

J Nucl Cardiol. 2003 Mar-Apr;10(2):132-9.PMID: 12673177 [PubMed - indexed for MEDLINE]Related articles

Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma.

Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A, Sabbah A, Woronoff-Lemsi MC, Cahn JY.

Ann Oncol. 2003 Feb;14(2):277-81.PMID: 12562656 [PubMed - indexed for MEDLINE]Related articlesFree article

[Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy]

Elbl L, Vásová I, Navrátil M, Vorlícek J, Malásková L, Spinar J.

Vnitr Lek. 2006 Jun;52(6):563-70. Czech. PMID: 16871759 [PubMed - indexed for MEDLINE]Related articles

Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.

Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M.

Med Pediatr Oncol. 2001 Jul;37(1):4-9.PMID: 11466716 [PubMed - indexed for MEDLINE]Related articles

Ventricular repolarization time indexes following anthracycline treatment.

Sarubbi B, Orditura M, Ducceschi V, De Vita F, Santangelo L, Ciaramella F, Catalano G, Iacono A.

Heart Vessels. 1997;12(6):262-6.PMID: 9860192 [PubMed - indexed for MEDLINE]Related articles

Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.

Jelić S, Radulović S, Nesković-Konstantinović Z, Kreacić M, Ristović Z, Bosnjak S, Milanović N, Vuletić L.

Support Care Cancer. 1995 May;3(3):176-82.PMID: 7655778 [PubMed - indexed for MEDLINE]Related articles

Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.

Choi BW, Berger HJ, Schwartz PE, Alexander J, Wackers FJ, Gottschalk A, Zaret BL.

Am Heart J. 1983 Oct;106(4 Pt 1):638-43.PMID: 6613807 [PubMed - indexed for MEDLINE]Related articles

Late cardiotoxicity after treatment for a malignant bone tumor.

Postma A, Bink-Boelkens MT, Beaufort-Krol GC, Kengen RA, Elzenga NJ, Schasfoort-van Leeuwen MJ, Schraffordt koops H, Kamps WA.

Med Pediatr Oncol. 1996 Apr;26(4):230-7.PMID: 8600333 [PubMed - indexed for MEDLINE]Related articles

Systolic and diastolic cardiac dysfunction early after the initiation of doxorubicin therapy: significance of gender and concurrent mediastinal radiation.

Clements IP, Davis BJ, Wiseman GA.

Nucl Med Commun. 2002 Jun;23(6):521-7.PMID: 12029206 [PubMed - indexed for MEDLINE]Related articles